Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) common stock between July 1, 2021 and June 26, 2024, inclusive (the “Class Period”). Walgreens investors have until November 18, 2024 to file a lead plaintiff motion.

If you suffered a loss on your Walgreens investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Walgreens-Boots-Alliance-Inc-2/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On June 27, 2023, Walgreens released its third quarter fiscal 2023 financial results, falling below analysts’ expectations. Additionally, the Company lowered its fiscal 2023 guidance due to “a slower profit ramp for U.S. health care” related to “reduced COVID, cold and flu season and softer market demand.”

On this news, Walgreens’ stock price fell $2.95, or 9.3%, to close at $28.64 per share on June 27, 2023, thereby injuring investors.

Then, on January 4, 2024, Walgreen released its first quarter fiscal 2024 financial results, falling short of expectations due to “operations in their co-located VillageMD/Walgreens centers.” On this news, Walgreens’ stock price fell $1.31, or 5.1%, to close at $24.26 per share on January 4, 2024.

Then, on June 27, 2024, Walgreens released its third quarter fiscal 2024 financial results, once again falling below analysts’ expectations and lowering its fiscal 2024 guidance. The Company stated that, while it “believe[s] in the future of [VillageMD] and intend[s] to remain an investor and partner . . . as part of [its] persistent focus on value creation for [Walgreens], [it is] collaborating with leadership toward an endpoint.”

On this news, Walgreens’ stock price fell $3.47, or 22.2%, to close at $12.19 per share on June 27, 2024, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) despite repeated assurances, Walgreens was not disciplined about deploying capital to grow the U.S. Healthcare segment and did not know how to work with and scale the VillageMD model; (2) Walgreens was not able to profitably scale VillageMD to support the Company’s long-term growth initiatives; (3) Walgreens’ rollout of VillageMD clinics was not going according to plan; (4) Walgreens’ U.S. Healthcare segment was experiencing slower growth than expected because Walgreens had oversaturated markets with VillageMD clinics, leading these newly created medical clinics to be understaffed and see fewer patients; (5) Walgreens executives had failed to manage investor expectations regarding the negative impact that the VillageMD expansion would have on Walgreens’ short-term profits, overstatement of the value of VillageMD, and the risk that the Company would be forced to divest part or all of its stake in VillageMD; and (6) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Walgreens common stock during the Class Period, you may move the Court no later than November 18, 2024 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241001469723/en/